Your session is about to expire
← Back to Search
Rosuvastatin with/without ARV-471 for Healthy Subjects
Study Summary
This trial explores how a medication (ARV-471) affects how another medication (rosuvastatin) is absorbed in healthy adults. Participants stay at the clinic for 10 days.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Does this research involve participants of any age, including those over forty?
"This research requires participants to be legally of age (18+) and no older than 65."
Has the combination of Rosuvastatin and ARV-471 been given formal authorization by the FDA?
"Our internal safety assessment calculated a score of 1 for the combination of Rosuvastatin and ARV-471. This is based on this being an early phase trial, meaning there are limited clinical data that support its efficacy or safety profile."
What is the current enrollment criterion for this clinical experiment?
"Absolutely. Clinicaltrials.gov displays that this research is currently enrolling patients, with the trial first posted on December 9th 2022 and last edited on December 29th 2022. At present, 12 individuals are needed to partake in the study at 1 location."
Are volunteers still being welcomed for this experiment?
"Affirmative. According to clinicaltrials.gov, this medical experiment is still recruiting participants as of December 29th 2022; it was first advertised on the 9th of December that same year. Just 12 people need to be enrolled between a single location."
Who is eligible to partake in the research study?
"This medical experiment is recruiting 12 healthy adults aged 18 to 65 with a Body Mass Index (BMI) between 17.5 and 32 kg/m2, as well as total body weight of at least 45kg., Male or female candidates must pass a comprehensive physical examination alongside laboratory tests, vital signs testing, ECGs etc. Furthermore, all participants are needed to have the capacity for informed consent prior to joining the trial."
What is the purpose of this research endeavor?
"The aim of this trial is to determine the maximal plasma concentration (Cmax) of rosuvastatin when administered alone. This will be assessed via 1-day predose and postdose measurements at hours 1, 2, 3, 4, 6, 8 12 24 36 48 72. Secondary objectives include assessing adverse events/serious adverse events in patients as well as determining any clinically significant changes from baseline vital signs such as blood pressure or pulse rate after a 5 minute rest period while lying down."
Share this study with friends
Copy Link
Messenger